Last checked: October 29, 2026. This page explains how the rules work. It is not legal advice; talk to a qualified attorney about your situation.
The 30-second answer
Yes, for genuine lab research, as long as nothing points to human use. FDA judges the whole storefront, not just the "research use only" label. Pharmacies are a separate lane. Since October 28, 2026, HHS allows narrow 503A compounding of six peptides, by prescription only.
Same vial, two legal answers
Picture two identical vials: same powder, same "research use only" label. One is a lawful lab reagent. The other is an unapproved drug in FDA's eyes.
The difference isn't in the vial. It's everything around it: the website, the emails, and what's sold in the same cart.
In this article you'll learn:
- The three legal lanes for peptides, and why they never merge
- What a "research use only" label does, and what it can't do
- How 503A, 503B, Category 2 and the October 28 HHS policy fit together
What are the three legal lanes for peptides?
A peptide is a short chain of amino acids. Picture Lego bricks: a peptide is a short chain, and a protein is the whole castle. US law sorts peptides into three lanes.
| Lane | What it is | Human use? | The rule that governs it |
|---|---|---|---|
| FDA-approved drug | A finished product with an approved application, such as semaglutide or tirzepatide brands | Yes, by prescription | FD&C Act §505 approval |
| Compounded drug | A pharmacy-made preparation for a patient, from a 503A pharmacy or 503B outsourcing facility | Yes, by prescription | §503A or §503B conditions. Not FDA-approved |
| Research-grade peptide | A lab reagent for test-tube or animal research, from a research chemical supplier | No | Intended use (21 CFR 201.128) and the research-shipment rule (21 CFR 312.160) |
The lanes don't mix. A research-grade vial doesn't become a compounded drug. And a compounding policy doesn't make research-grade material fit for patients.
How does FDA decide what a product is?
It looks at intended use. As FDA's warning letters put it, the law defines a drug largely by purpose. That includes articles intended for use in disease, or intended to affect the body's structure or function. [4]
So the seller's intent is the pivot. FDA's regulation calls it "objective intent." The evidence can include "such persons' expressions, the design or composition of the article," and "the circumstances surrounding the distribution of the article." [1]
Think of a bottle labeled "not for drinking," sold next to cups and a recipe card. Nobody believes the label. FDA reads a peptide storefront the same way.
In its August 24, 2026 letter to one peptide seller, FDA cited three kinds of evidence: [4]
- Study summaries framed as body effects. Product pages said a lab study "suggests" a peptide "could be a potential" therapy for a named disease.
- Bundled injection supplies. Bacteriostatic water sold alongside the peptides.
- The products themselves. FDA called injectable peptides "especially concerning from a public health perspective."
The result: each product was an unapproved new drug. Shipping it across state lines broke federal law. FDA has sent letters on this pattern since at least December 2024. [13]
Did you know? FDA said bacteriostatic water sold next to peptides gave buyers "the means to prepare an injectable drug for human administration." One add-to-cart item became evidence in a federal warning letter. [4]
What this means for you: The label is one clue among many. If the rest of the store talks about people, FDA classifies the product as a drug for people.
What does a "research use only" label actually do?
FDA has a specific rule for shipping a new drug only for test-tube or lab-animal research. It sets three conditions: [2]
- Exact label wording, which ends "Not for use in humans."
- Due diligence: the shipper must check that the buyer actually runs that kind of research.
- Records: who got each shipment, when, how much and which batch, kept for 2 years.
FDA can end that permission if a drug "is used for purposes other than bona fide scientific investigation."
| A research label does | A research label doesn't |
|---|---|
| State the product's intended use | Override dosing charts, human-use claims or customer messages |
| Form one part of the 312.160 framework | Replace buyer checks and shipment records |
| Signal that the product isn't for people | Make a product fit, tested or legal for human use |
| Match a research supplier's real business, if the storefront agrees | Protect clinics. Ohio says clinics can't possess these drugs at all |
What this means for you: A good research supplier keeps the whole picture consistent. No dosing, no human-use claims, no injection kits. Plus a COA (a lab report card for one batch) showing what's in the vial.
How to read one: How to read a certificate of analysis
What's the difference between 503A and 503B?
Compounding is how a patient can legally get a peptide with no approved product. It runs through two sections of federal law.
Think of bakeries. A 503A pharmacy is the neighborhood bakery making one custom cake to order. A 503B outsourcing facility is the commercial bakery making batches under factory inspection.
| 503A | 503B | |
|---|---|---|
| Who | A pharmacist in a state-licensed pharmacy or federal facility, or a licensed physician | An outsourcing facility registered with FDA |
| Prescriptions | A patient-specific prescription is required | Can compound with or without patient-specific prescriptions |
| Quality rules | Not under CGMP (FDA's factory quality rules); USP and state rules apply | Under CGMP |
| Main overseer | State boards of pharmacy | FDA, on a risk-based schedule |
| 2026 peptide status | HHS interim policy covers 6 peptides | Not covered by the HHS policy |
Sources: FDA compounding Q&A; 21 U.S.C. 353b; HHS policy. [5] [14] [7]
What changed for peptides in 2026?
Two terms first:
- Category 2 was FDA's red-flag shelf for compounding: nominated ingredients it said raised significant safety risks.
- Enforcement discretion means an agency chooses not to enforce a rule under set conditions. It's like a city saying it won't ticket cars on one street while it rewrites the parking rules. The rule itself hasn't changed.
The short timeline:
- April 22, 2026: BPC-157, TB-500, KPV, MOTS-c, epitalon, semax and others leave Category 2 after their nominators withdrew.
- July 23–24: FDA's advisory committee recommends six of seven peptides for the 503A bulks list (FDA's approved-ingredient pantry for pharmacies). FDA staff had advised against all seven.
- October 28: HHS issues an interim enforcement-discretion policy for 503A compounding of BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. [7]
| What changed on Oct 28 | What didn't change |
|---|---|
| 503A pharmacies and physicians have a narrow pathway for six peptides | None of them is FDA-approved |
| Named forms and routes, prescription only | 503B outsourcing facilities aren't covered |
| A strict COA graded "Intended for human drug compounding" | None is on the bulks list. Rulemaking continues |
| Single-ingredient products and MedWatch reporting required | Research-grade products aren't covered, and still can't be sold for human use |
Did you know? HHS framed the policy partly as a way to "discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers." [7]
What this means for you: The federal government sees research material and patient care as separate channels. The 2026 changes widened the pharmacy channel, not the research one.
Full detail: The FDA's July 2026 peptide vote, explained
Do state laws differ?
Yes. Federal law sets the floor. States add licensing, pharmacy and consumer-protection rules on top, and state boards run day-to-day oversight of pharmacies. [5]
Ohio is the most explicit published example we found. Its Board of Pharmacy guidance, updated December 8, 2025, says: [9]
- Clinics must not "order, possess, or administer any drugs labeled 'for research purposes only.'" Doing so is "a violation of state and federal law, regardless if the patient 'consents.'"
- Peptides "such as BPC-157" in FDA Category 2 or 3 "cannot be compounded."
- The Board has summarily suspended "more than 30 clinics and medical spas" since early 2025.
That guidance predates the April and October 2026 federal changes. On October 28, Reuters quoted the American Peptide Association's co-founder warning that states aren't bound to follow the federal move. [12]
We haven't surveyed all 50 states. Check these three places:
- Your state board of pharmacy's position on peptide compounding and research-labeled products
- Your state medical board's rules for clinics and med spas
- Your institution's research compliance office, for purchasing rules on unapproved compounds
What other rules apply?
- Sport. WADA's Prohibited List names BPC-157 under S0, non-approved substances, banned at all times. S0 covers any substance without approval from a government health authority. [10]
- Animals. Selling peptides for use in pets makes them unapproved animal drugs. Are peptides legal for dogs and cats?
Myth vs. fact
| Myth | Fact |
|---|---|
| "A 'research use only' label makes the sale legal." | FDA judges the whole storefront. Its letters found drugs for human use despite those labels. |
| "The 2026 HHS policy legalized peptides for people." | It covers 503A compounding of six peptides, by prescription. Research products aren't covered. |
| "Compounded means FDA-approved." | Compounded drugs are not FDA-approved. FDA doesn't review them before they're sold. |
| "If it's federal, every state goes along." | States set their own rules. Ohio bars clinics from possessing research-labeled drugs. |
What should a researcher do next?
Run this five-point legal-hygiene checklist:
- Buy for a defined protocol (test-tube or animal work) and write it down.
- Expect the supplier to ask about your work. Checking buyers is part of the 312.160 framework.
- Demand a lot-matched COA with identity by two methods, HPLC purity, endotoxin and the lab's name.
- Walk away from human-use signals: dosing charts, "protocols," before/after stories, or injection kits sold alongside.
- Keep records of what arrived, its lot number and how you stored it.
Read next:
- Is BPC-157 legal? 2026 status
- BPC-157 research overview
- Is Peptide Sciences shut down?
The evidence in detail
The legal hooks in FDA's warning letters
In the August 24, 2026 letter, FDA found each product was an unapproved new drug under section 505(a) of the FD&C Act. Introducing it into interstate commerce violated sections 301(d) and 505(a). The December 10, 2024 letter reached the same conclusion "despite statements on your product labeling marketing your products as 'RESEARCH USE ONLY.'" [4] [13]
The research-shipment rule, word for word (21 CFR 312.160)
- Label: "CAUTION: Contains a new drug for investigational use only in laboratory research animals, or for tests in vitro. Not for use in humans."
- Due diligence: the shipper must "use due diligence to assure that the consignee is regularly engaged in conducting such tests."
- Records: name and address of the recipient, date, quantity and batch for each shipment, kept for 2 years and open to FDA on request.
503A vs 503B, full detail
| 503A | 503B | |
|---|---|---|
| Created by | FD&C Act §503A | The 2013 Drug Quality and Security Act |
| Prescriptions | Patient-specific prescription required | Can compound with or without prescriptions for identified individual patients, so it can supply clinics' "office stock" (21 U.S.C. 353b(d)(4)(C); 2023 Federal Register 503B notice) |
| FDA's role | Surveillance and for-cause inspections | Primary overseer; risk-based inspection schedule |
| Allowed bulk ingredients | USP/NF monograph, component of an approved drug, or on the 503A bulks list | Separate 503B "clinical need" bulks list |
The 2026 peptide changes, in full
FDA removed BPC-157, TB-500, KPV, MOTS-c, epitalon, semax and six other peptides from 503A Category 2 after their nominators withdrew. HHS dates the end of Category 2 status to April 22, 2026. On July 23–24, FDA's advisory committee recommended six of seven peptides for the 503A bulks list, against FDA staff advice.
On October 28, HHS said it doesn't intend to act against 503A compounders using BPC-157, epitalon, KPV, MOTS-c, semax or TB-500. The conditions: named forms and routes, a prescription, a full COA graded "Intended for human drug compounding," single-ingredient products and MedWatch reporting. The policy appears in the Federal Register as doc. 2026-22192, scheduled for October 30, 2026. [7]
Not legal advice. This page summarizes public federal and state sources as of the date above. Laws, guidance and enforcement policies change; consult a qualified attorney about your situation.
For research use only. Not for human consumption. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
References
- eCFR. 21 CFR 201.128, Meaning of "intended uses." www.ecfr.gov/current/title-21/part-201/section-201.128
- eCFR. 21 CFR 312.160, Drugs for investigational use in laboratory research animals or in vitro tests. www.ecfr.gov/current/title-21/part-312/section-312.160
- FD&C Act §201(g)(1), 21 U.S.C. 321(g)(1). www.govinfo.gov/link/uscode/21/321
- FDA. Warning Letter 735063, Aug 24, 2026. www.fda.gov/inspections-compliance-enforcement-and-criminal-investigat…
- FDA. Compounding and the FDA: Questions and Answers. www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions…
- FDA. Bulk Drug Substances Used in Compounding Under Section 503A. www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-com…
- HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretio… ; Federal Register doc. 2026-22192 (publication Oct 30, 2026): public-inspection.federalregister.gov/2026-22192.pdf
- FDA. PCAC July 23–24, 2026 meeting page. www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24…
- Ohio Board of Pharmacy. Ten Common Prescriber Clinic and Medical Spa Violations (updated 12/8/2025). www.pharmacy.ohio.gov/documents/pubs/special/ivtherapy/ten%20common%20…
- WADA. The Prohibited List. www.wada-ama.org/en/prohibited-list
- Federal Register. List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (May 1, 2026). www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-d…
- Secondary: Reuters, "US Health Secretary Kennedy opens access to some unapproved peptides," Oct 28, 2026. www.reuters.com/legal/litigation/us-health-department-allow-temporary-…
- FDA. Warning Letter 695607, Dec 10, 2024 (research-use-only peptides found to be unapproved new drugs). www.fda.gov/inspections-compliance-enforcement-and-criminal-investigat… (opened 2026-10-29 in the reader-first pass)
- 21 U.S.C. 353b(d)(4)(C), Outsourcing facilities ("An outsourcing facility may or may not obtain prescriptions for identified individual patients."). govinfo.gov/content/pkg/USCODE-2014-title21/html/USCODE-2014-title21-c… ; current text: uscode.house.gov/view.xhtml?edition=prelim&num=0&req=granuleid… (seen via government search 2026-10-29); FDA notice, "List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B," Aug 21, 2023 (outsourcing facilities can distribute compounded drugs to practitioners for "office stock"). federalregister.gov/documents/2023/08/21/2023-17881/list-of-bulk-drug-… (excerpt seen via government search 2026-10-29)
Research use only
This article is provided for educational and informational purposes and summarizes published laboratory and preclinical research. All ProGrade Peptides products are sold strictly for in-vitro laboratory and research use only (RUO). Nothing here is medical advice, a therapeutic claim, or a protocol for human or animal use. These compounds are not intended to diagnose, treat, cure, or prevent any disease.
Frequently asked questions
Selling and buying peptides for genuine lab research is a recognized activity. FDA's intended-use rule and its research-shipment rule govern it. Marketing or using them for people turns them into unapproved new drugs.
No. FDA looks at the seller's full presentation. Its 2026 warning letters found products were drugs for human use despite "research use only" labels, based on website claims and bundled bacteriostatic water.
503A covers state-licensed pharmacies and physicians compounding for individual patients on prescriptions, overseen mainly by states. 503B covers FDA-registered outsourcing facilities that follow CGMP and face FDA inspection.
No. The October 28, 2026 policy covers 503A compounding of six peptides from FDA-registered, CGMP-compliant makers, with a prescription. HHS described it as a way to move patients away from research-use-only products.
Not in Ohio. Its Board of Pharmacy says clinics can't possess drugs labeled "for research purposes only." Other states set their own rules, so check your state board.
Drafted with AI assistance and fact-checked against the cited sources by The ProGrade Research Desk. See our editorial policy and sourcing policy. Spot an error? Report it.
